Product Launchintraocular lensmedtechophthalmologyjohnson johnson
Johnson & Johnson Gains FDA Approval, Barclays Raises Target
|
5.1
Johnson & Johnson on March 12 received FDA approval for the TECNIS PureSee intraocular lens, an extended depth-of-focus IOL reporting 97% of patients with no very bothersome visual disturbances and expected U.S. availability later in 2024. On March 19 Barclays raised its price target to $234 from $217 after noting 23% U.S. pharma growth ex‑Stelara, and it increased estimates while maintaining an Equal Weight rating.
Scoring Rationale
Credible FDA approval and Barclays upgrade drive actionable commercial news; limited novelty and narrow ophthalmology scope restrict impact.
Practice interview problems based on real data
1,500+ SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems
